Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_3

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

unknown1

Completed1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

unknown133%

completed133%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Clinical Study on the Prevention of Surgical Wound Complications for Aneurysmal Thoracic-abdominal Aortic Pathology Using the "PREVENA" System

NCT03512470

unknownphase_2

Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction

NCT03448510

terminatedphase_3

Renal Denervation by Allegro System in Patients With Resistant Hypertension

NCT01874470

Clinical Trials (3)

Showing 3 of 3 trials

NCT03512470Not Applicable

Clinical Study on the Prevention of Surgical Wound Complications for Aneurysmal Thoracic-abdominal Aortic Pathology Using the "PREVENA" System

Completed

NCT03448510Phase 2

Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction

Unknown

NCT01874470Phase 3

Renal Denervation by Allegro System in Patients With Resistant Hypertension

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3